芬兰百日咳杆菌SphB1毒力因子多态性与无细胞疫苗接种前后抗原表达变化
该研究对芬兰1991-2020年273株百日咳杆菌临床分离株进行sphB1基因分型,并与菌毛血清型及抗原表达关联。无细胞疫苗引入前95.5%为野生型sphB1-1,变异型sphB1-2和sphB1-3频率随时间上升至2016-2020年的100%。携带变异型的菌株FHA、ACT和PT表达显著升高,提示菌株适应涉及毒力因子加工优化。
要点
- 芬兰无细胞疫苗引入后sphB1变异型占比升至100%。
- sphB1变异株FHA、ACT、PT表达显著高于野生型。
- sphB1-3仅与Fim3血清型关联,sphB1-2分布于Fim2和Fim3。
核心结论
- sphB1突变与FHA/ACT表达升高相关,提示百日咳杆菌适应不仅涉及抗原漂移,还包括毒力因子加工优化,可能促进百日咳再现。
研究设计与样本
- 对芬兰1991-2020年收集的273株临床分离株进行sphB1基因分型(PCR和Sanger测序),并与菌毛血清型、ptxP和prn基因型及ACT、FHA、PT、PRN表达水平关联分析。
主要发现
- 无细胞疫苗引入前(2005年前),95.5%的分离株携带野生型sphB1-1。
- 变异型sphB1-2(c.358G>A,p.Val120Ile)和sphB1-3(c.463G>A,p.Ala155Thr)频率随时间增加,2016-2020年达到100%。
- 两种变异型均于2003年在ptxP3谱系中出现。
- sphB1-3基因型仅与Fim3血清型关联,而sphB1-2分布于Fim2和Fim3血清型。
临床怎么用
- 监测百日咳杆菌sphB1基因型及抗原表达变化,可辅助评估疫苗压力下的菌株适应性演化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bordetella pertussis has adapted significantly following the transition from whole-cell vaccines (WCV) to acellular vaccines (ACV). While changes in vaccine antigens are well-documented, the evolution of processing factors like sphB1, a protease essential for the maturation of filamentous hemagglutinin (FHA) and adenylate cyclase toxin (ACT), remains unexplored. This study was aimed to characterize sphB1 genotypes among circulating isolates collected in Finland during 1991-2020 and their association with different antigen expressions. MATERIAL AND METHODS: Altogether, 273 selected clinical isolates were analysed. The sphB1 gene was genotyped using PCR and Sanger sequencing. Results were correlated with fimbrial (Fim) serotypes, ptxP and prn genotypes, and expression levels of ACT, FHA, pertussis toxin (PT), and pertactin (PRN). RESULTS: Prior to ACV introduction in 2005, 95.5% of isolates carried wildtype sphB1-1. However, frequencies of variant genotypes sphB1-2 (c.358G > A, p. (Val120Ile)) and sphB1-3 (c.463G > A, p. (Ala155Thr)) increased with time reaching 100% during 2016-2020. Both variants emerged in 2003 within the ptxP3 lineage. Isolates carrying sphB1 variant genotypes were associated with significantly higher FHA (1.7-fold), ACT (1.6-fold) and PT (1,2-fold) (all p values <0.001) expression levels than isolates carrying the wildtype allele. Furthermore, sphB1-3 genotype was exclusively associated with Fim3 serotype, whereas sphB1-2 was distributed across both Fim2 and Fim3 serotypes. CONCLUSIONS: The association between sphB1 mutations and elevated FHA/ACT expressions suggests that B. pertussis adaptation involves not only antigenic shifts but also optimized processing of key virulence factors. These lineage-specific combinations may play a critical role in pertussis resurgence.
引用
- Niinikoski V, Myllylä A, Barkoff AM, et al. Polymorphisms in the Bordetella pertussis virulence factor SphB1 and altered antigen expression of clinical isolates before and after acellular pertussis vaccination in Finland. Vaccine. 2026. PMID: 42531982. doi:10.1016/j.vaccine.2026.128979
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。